Dan RohintonEli Lilly & Co.LLYWAITSep 02, 2026

Pharma and biotech are seeing better leadership in the market. Partly because these sectors are going to be big implementers of AI, and the sector was out of favour for quite some time. They tend to be pretty big cash generators.

He's a big fan of focusing on the leaders in a sector -- easier time hiring best employees and raising capital. He'd much prefer this over PFE. Lots of revenue upside. GLP-1 market will continue to grow, as these drugs help with all kinds of issues.

Don't put new $$ in today. Priced to perfection on its execution abilities. At some point it will stumble. Good company, but very expensive.

Consistent earnings, fair valuation, and a great drug pipeline.

Is up 370% over 5 years, but really started to rise in 2023. He expects revenue growth to consistently build in coming quarters. Trading at all-time highs now.

Was upgraded today. It's the highest-quality healthcare stock. They have more than just the GLP-1 drug; are diverse with their entire drug catalogue. Exceptional execution. Good PE. 

Broad pipeline, but its leadership in GLP-1 is what's really pushing the stock. New catalyst is approval for oral pill. Winning battle against NVO. Sees ~25% earnings growth rate over next several years. 

Broken out to a new space on the charts. He looks to buy on dips if possible. Yield is 0.57%.

Different businesses. LLY is a big play in GLP-1 drugs. How will pills effect the injections business? LLY has done a good job of navigating these new pills. GS enjoys increased stock market and IPO businesses. He prefers LLY, which is tied to a secular growth trend, but GS' good times in capturing revenue in this cycle will end.

Better product than NVO. So he'd be buying this one (but not at today's price ;)

Their earnings and drugs are coming through. They have momentum and are building factories to produce their GLP-1 weight-loss drug. Is a huge holding for him.

Clear leader in diabetes and weight loss. Other players are coming in, but this name is ahead of the curve. Very strong earnings growth over next few years (50% for 2026, 22% for 2027, 17% for 2028). Reliable aspects of a pharmaceutical healthcare name, plus very strong earnings growth.

RSI is 70, so wait for a bit of a pullback.

Largest pharma company in the US, and possibly the world. Breaking out to fresh all-time highs. Leading GLP-1 drugs. 150-year history of healthcare innovation. 

Obesity + diabetes comprise ~55% of revenues, and growing fast. Also into oncology, immunology, neuroscience, and more. Well-insulated from patent cliffs. 80% of marketed drugs are "biologic", which stand up better to generic competition. Prolific FCF. M&A frenzy this year on top of pretty robust R&D. Yield is 0.61% (growing 15% compound pace over last 5 years, should continue).

Has owned a long time in the growth fund. It is a leader in GLP 1. Every year the weight loss drugs seem to be able to treat another condition so it is a bit of a miracle drug. Is still early for these drugs. It is expensive so if you want something else you could try Thermo Fisher for broad exposure. The health care sector still has an overhang from Covid and the US government has pulled back on spending.

His preference in the space.

NVO chart's under pressure. Where are we in the saturation cycle for GLP-1 penetration? Also, what will the price/volume dynamics be, since NVO kicked off a price war?

LLY has the better position in terms of branded drugs. Hasn't pulled the trigger on either.